FOCAL SEGMENTAL GLOMERULOSCLEROSIS

This study tests a noninvasive device that stimulates a nerve in the ear to help children with steroid-resistant nephrotic syndrome, a kidney condition that doesn't respond to standard steroids. The device aims to calm the immune system and reduce inflammation, potentially allowi…

This study tests a drug called sparsentan in 20 adults who have had a kidney transplant and still have protein in their urine due to IgA nephropathy or FSGS. The goal is to see if the drug can safely reduce protein levels over 36 weeks. Participants take one pill daily, and the s…

This study tests an oral drug called sparsentan in 67 children with certain kidney diseases that cause protein in the urine. The goal is to see if the drug safely reduces protein leakage and helps control the disease over about two years. Participants take the drug once daily, an…

This study tests a new drug, praliciguat, for people with a kidney disease called focal segmental glomerulosclerosis (FSGS). About 60 adults will be randomly assigned to take either the drug or a placebo for 24 weeks, followed by 24 weeks where everyone gets the drug. The main go…

This study tests whether the diabetes drug metformin can protect kidney cells in people with Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease. About 30 adults will receive either extended-release metformin or a placebo alongside their usual treatments for 6 months…

This study tests three experimental drugs (frexalimab, brivekimig, and rilzabrutinib) in people aged 16 to 75 with two rare kidney diseases: FSGS and MCD. The goal is to see if these drugs can reduce protein in the urine and help achieve remission. Participants will receive one o…

This study tests an oral medication called BI 764198 for people with a kidney disease called focal segmental glomerulosclerosis (FSGS). About 286 adults and teens will take either the study drug or a placebo once daily for up to 2 years, while continuing their usual FSGS treatmen…

This small pilot study is testing whether a gentle, non-invasive nerve stimulation device worn on the ear can help children with a frequently relapsing kidney disease. The goal is to see if this approach can reduce disease flare-ups and the need for strong steroid medications. Re…

This study is testing whether an oral powder called ManNAc can help people with FSGS, a disease that causes kidney scarring. Thirty adults with FSGS will take the powder dissolved in water twice daily for 14 weeks. Researchers will check if it safely reduces protein in the urine,…

This study helps people with certain kidney diseases (like nephrotic syndrome and FSGS) find clinical trials that might be a good fit for their specific condition. Researchers use advanced molecular testing to match each person's unique disease profile to targeted therapies being…

This study is gathering information and biological samples from 300 people with FSGS or MCD who have had or will have a kidney transplant. Researchers want to learn why the disease sometimes comes back after transplant, which can lead to graft loss. The goal is to create a shared…